Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 5/20 | 0.43 |
| ▸ | CNR1 | P21554 | 3/20 | 0.43 |
| ▸ | CNR2 | P34972 | 3/20 | 0.43 |
| ▸ | PRKCG | P05129 | 1/20 | 0.43 |
| ▸ | PRKCB | P05771 | 1/20 | 0.43 |
| ▸ | PRKCA | P17252 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 7/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4851450 | 0.90 | GSK3B (0.44) | PRKCGPRKCBPRKCAGSK3BKCNH2 | |
| SCHEMBL4851848 | 0.89 | KDM4E (0.46) | CNR1CNR2PRKCGPRKCBPRKCA | |
| SCHEMBL4843346 | 0.81 | MPO (0.42) | CNR1CNR2 | |
| SCHEMBL4849894 | 0.79 | MEN1 (0.42) | — | |
| SCHEMBL10831892 | 0.79 | BCHE (0.45) | BCHECNR1CNR2PRKCGPRKCB | |
| SCHEMBL4850204 | 0.79 | GSK3B (0.46) | PRKCGPRKCBPRKCAGSK3BKCNH2 | |
| SCHEMBL4848849 | 0.79 | RXRA (0.38) | CNR1CNR2KCNH2 | |
| SCHEMBL10831053 | 0.78 | BCHE (0.46) | BCHECNR1CNR2PRKCGPRKCB | |
| SCHEMBL10830928 | 0.78 | BCHE (0.46) | BCHECNR1CNR2PRKCGPRKCB | |
| SCHEMBL10831465 | 0.78 | BCHE (0.47) | BCHECNR1CNR2HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7329657-B2 | Indazolyl-substituted pyrroline compounds as kinase inhibitors | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2008-02-12 | — | — | US | disclosed |
| US-7304060-B2 | Indazolyl-substituted pyrroline compounds as kinase inhibitors | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2007-12-04 | — | — | US | disclosed |
| US-20050004202-A1 | Indazolyl-substituted pyrroline compounds as kinase inhibitors | ZHANG HAN-CHENG (US) | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004202-A1 | Indazolyl-substituted pyrroline compounds as kinase inhibitors | MAP2K2, MAP3K20, MAP2K3 | BCHE 3816/4885CNR1 3510/4885CNR2 3453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.